<i>TP53</i> mutant <i>MDM2</i>-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation

Catherine J. Drummond(Newcastle University), John Lunec(Newcastle University)

Oncotarget

June 15, 2016

10.18632/oncotarget.10073

Cited by 21

Related Papers

Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma

|British Journal of Cancer|2017|63

Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2

|British Journal of Cancer|2004|53

ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma

|Cancers|2018|39

Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients

|BMC Cancer|2020|16

Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition

|International Journal of Molecular Sciences|2023|15